<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genet</journal-id><journal-title>BMC Genetics</journal-title><issn pub-type="epub">1471-2156</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2156-7-34</article-id><article-id pub-id-type="pmid">16749937</article-id><article-id pub-id-type="doi">10.1186/1471-2156-7-34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association study of the trinucleotide repeat polymorphism within <italic>SMARCA2 </italic>and schizophrenia</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Sengupta</surname><given-names>Sarojini</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>sarojini.sengupta@douglas.mcgill.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Xiong</surname><given-names>Lan</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>lan.xiong@elf.mcgill.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Fathalli</surname><given-names>Ferid</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>ferid.fathalli@douglas.mcgill.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Benkelfat</surname><given-names>Chawki</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>chawki.benkelfat@mcgill.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Tabbane</surname><given-names>Karim</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>k_tabbane@yahoo.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Danics</surname><given-names>Zoltan</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>zdanics@axelero.hu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Labelle</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>alabelle@rohcg.on.ca</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Lal</surname><given-names>Samarthji</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>samarthji.lal@douglas.mcgill.ca</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Krebs</surname><given-names>Marie-Odile</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>krebs@broca.inserm.fr</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Rouleau</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>guy.rouleau@mcgill.ca</email></contrib><contrib id="A11" corresp="yes" contrib-type="author"><name><surname>Joober</surname><given-names>Ridha</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>ridha.joober@douglas.mcgill.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Human Genetics, McGill University, Montreal, Canada</aff><aff id="I2"><label>2</label>Douglas Hospital Research Centre, Montreal, Canada</aff><aff id="I3"><label>3</label>Department of Psychiatry, McGill University, Montreal, Canada</aff><aff id="I4"><label>4</label>Center for the Study of Brain Diseases, Notre Dame Hospital, Montreal, Canada</aff><aff id="I5"><label>5</label>Department of Psychiatry, University of Tunis, Tunis, Tunisia</aff><aff id="I6"><label>6</label>National Institute of Psychiatry, Budapest, Hungary</aff><aff id="I7"><label>7</label>Department of Psychiatry, University of Ottawa, Ottawa, Canada</aff><aff id="I8"><label>8</label>Service Hospitalo-Universitaire, H&#x000f4;pital Sainte-Anne, Paris, France</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2006</year></pub-date><volume>7</volume><fpage>34</fpage><lpage>34</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2156/7/34"/><history><date date-type="received"><day>2</day><month>1</month><year>2006</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Sengupta et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Sengupta et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Sengupta Sarojini sarojini.sengupta@douglas.mcgill.ca </dc:author><dc:title> Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Genetics 7(1): 34-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2156(2006)7:1&#x0003c;34&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2156</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Brahma (BRM) is a key component of the multisubunit SWI/SNF complex, a complex which uses the energy of ATP hydrolysis to remodel chromatin. BRM contains an N-terminal polyglutamine domain, encoded by a polymorphic trinucleotide (CAA/CAG) repeat, the only known polymorphism in the coding region of the gene (<italic>SMARCA2</italic>). We have examined the association of this polymorphism with schizophrenia in a family-based and case/control study. <italic>SMARCA2 </italic>was chosen as a candidate gene because of its specific role in developmental pathways, its high expression level in the brain and some evidence of its association with schizophrenia spectrum disorder from genome-wide linkage analysis.</p></sec><sec><title>Results</title><p>Family-based analysis with 281 complete and incomplete triads showed that there is no significant preferential transmission of any of the alleles to the affected offspring. Also, in the case/control analysis, similar allele and genotype distributions were observed between affected cases (n = 289) and unaffected controls (n = 273) in each of three Caucasian populations studied: French Canadian, Tunisian and other Caucasians of European origin.</p></sec><sec><title>Conclusion</title><p>Results from our family-based and case-control association study suggest that there is no association between the trinucleotide repeat polymorphism within <italic>SMARCA2 </italic>and schizophrenia.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The SWI/SNF complex is a 2MDa, multi-subunit complex that uses the energy of ATP hydrolysis to disrupt nucleosome structure thereby increasing accessibility of transcription factors to their specific sites on DNA and histones. It is well conserved, with homologous complexes isolated from yeast, Xenopus, Drosophila and mammals [<xref ref-type="bibr" rid="B1">1</xref>]. SWI/SNF complexes purified from mammalian cell lines have been found to be heterologous with respect to their subunit composition, containing between 9&#x02013;12 subunits [<xref ref-type="bibr" rid="B2">2</xref>]. However, each complex contains Brahma (BRM), a DNA-dependant ATPase, or the related protein BRG1. The precise subunit composition of the complex appears to confer functional specificity via protein-protein interactions with specific transcription factors. BRM has been shown to be specifically required for activation by the androgen receptor [<xref ref-type="bibr" rid="B3">3</xref>]. In addition, BRM and not BRG1, interacts specifically with CBF-1 and ICD22, two components of the Notch signalling pathway, a pathway that controls cell fate commitment in several developmental processes [<xref ref-type="bibr" rid="B4">4</xref>]. Studies in mice have shown that high levels of BRM, in comparison to levels of BRG1, are present in brain tissue of the animals [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>BRM is encoded by the <italic>SMARCA2 </italic>gene. It is a member of the large, diverse SMARC (SWI/SNF-related, matrix-associated, actin-dependant regulator of chromatin) family. The only polymorphism within the encoding region of this gene is a stable, polymorphic trinucleotide repeat. We have carried out a case/control and family-based study to examine the association of this polymorphism with schizophrenia (SCZ).</p><p>Investigating <italic>SMARCA2 </italic>as a candidate gene for SCZ, is plausible for several reasons. First, genome-wide expression analysis of a post-mortem section of the dorsolateral prefrontal cortex of schizophrenia patients showed that <italic>SMARCA2 </italic>(also referred to as <italic>hSNFa</italic>) was upregulated 1.42-fold relative to non-affected controls [<xref ref-type="bibr" rid="B6">6</xref>]. Even though this upregulation of <italic>SMARCA2 </italic>has not been confirmed in other studies, several groups have demonstrated significant differences in mRNA levels in schizophrenic patients relative to controls. Gene expression profiles using post-mortem brain tissue (entorhinal cortex layer II stellate neurons) showed that 14% of the genes were up-regulated while 9% were down-regulated more than two-fold in the SCZ group relative to controls [<xref ref-type="bibr" rid="B7">7</xref>]. These results could be an indication that a global regulator of transcription may be involved in SCZ. BRM is one such global transcription regulator. BRM appears to be involved in the regulation of transcription (activation as well as repression) of a subset of genes. Genome-wide analysis, following deletion of SWI2 (the yeast homolog of BRM), showed that 1% of the 6,000 genes tested displayed more than a 3-fold change in mRNA levels, with some genes being up-regulated and others down-regulated [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>A second reason why an association between BRM and schizophrenia is plausible is that BRM appears to play an important role in cell development in general, and neuronal differentiation in particular and SCZ is believed to be a neurodevelopmental disorder [<xref ref-type="bibr" rid="B10">10</xref>]. Unlike BRG1, where levels are relatively constant in all cells, the cellular concentration of BRM increases during cell differentiation. Studies with neural cell cultures showed that BRM expression increased during differentiation from neural precursor cells to neural cells [<xref ref-type="bibr" rid="B11">11</xref>]. Kondo and Raff [<xref ref-type="bibr" rid="B12">12</xref>] provide evidence that the conversion of oligodendrocyte precursor cells to neural stem cells required the recruitment of BRM. Further, BRM has been shown to strongly associate with CBF-1 and ICD22, two components of the Notch signalling pathway which play a key role in cell fate commitment during development [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Finally studying BRM as a candidate gene is supported by some linkage studies. <italic>SMARCA2 </italic>is located on chromosome 9p22.3. Genome scan meta analysis indicated that region 9p22.3-21.1 demonstrated significant linkage (<italic>p </italic>&#x0003c; 0.01) with a schizoaffective-bipolar and bipolar-I disease model [<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>Results and discussion</title><p>BRM encapsulates several distinct domains including a polyglutamine domain, the DNA-dependant helicase domain and the bromodomain. The N-terminal polyglutamine domain is well conserved in mammals with glutamine-rich regions also present in the homologous Drosophila Brahma and <underline><italic>Saccharomyces cerevisiae</italic></underline> Swi2/Snf2 proteins (Figure <xref ref-type="fig" rid="F1">1</xref>). BRM is well conserved with the only known polymorphism within the coding region of the gene <italic>(SMARCA2) </italic>being a trinucleotide repeat (CAA/CAG) polymorphism. The most commonly occurring allele, corresponding to 32 trinucleotide repeats (181 bps, according to Genotyper<sup>&#x000ae; </sup>analysis) was designated the "0" allele. The two next most commonly occurring alleles were designated -1 (178 bps) and +1 (184 bps). Rare alleles -7, -5, +2, +3, and +4, having an allele frequency less than 0.01, were also obtained. Due to the problems that can arise in the cross-tabulation, since these cells had less than 5 cases each, the alleles were grouped for the statistical analyses- alleles -7, and -5 were grouped with the -1 allele and +2, +3, and +4 were grouped with the +1 allele.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>CLUSTAL W (1.82) multiple sequence alignment of the polyglutamine domain of mammalian BRM with the P/Q rich region in <italic>D. melanogaster </italic>and <italic>S. cerevisiae</italic>. Sequence alignment between BRM from <italic>Homo sapiens </italic>[GenBank: <ext-link ext-link-type="gen" xlink:href="NP_003061.3">NP_003061.3</ext-link>], <italic>Macau mulatta </italic>[GenBank: <ext-link ext-link-type="gen" xlink:href="AAV67666.1">AAV67666.1</ext-link>], <italic>Mus musculus </italic>[GenBank: <ext-link ext-link-type="gen" xlink:href="NP_035546.2">NP_035546.2</ext-link>], <italic>Rattus norvegius </italic>[GenBank: <ext-link ext-link-type="gen" xlink:href="NP_001004446.1">NP_001004446.1</ext-link>], <italic>D. melanogast</italic>er [GenBank: <ext-link ext-link-type="gen" xlink:href="P25439">P25439</ext-link>] and the homologous SNF2p from <italic>S. cerevisiae </italic>[GenBank: <ext-link ext-link-type="gen" xlink:href="NP_014933.1">NP_014933.1</ext-link>] was conducted.</p></caption><graphic xlink:href="1471-2156-7-34-1"/></fig><p>Case/control analysis was carried out to compare the allele and genotype frequency of the trinucleotide repeat polymorphism within three Caucasian populations: French Canadian, Tunisian and other Caucasians of European origin. Similar allele and genotype distributions were observed between affected cases and unaffected controls in each of these three populations (Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>). The alleles in the affected and non-affected populations were in Hardy-Weinberg equilibrium, calculated by considering each allele in combination with every other allele. The family-based association analysis (bi-allelic mode; additive model) showed that none of the alleles were preferentially transmitted/under-transmitted to the affected offspring (Table <xref ref-type="table" rid="T5">5</xref>). A minor under-transmission of the -1 allele (<italic>p </italic>= 0.034) was observed. However this effect was not significant when corrected for multiple testing.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Trinucleotide repeat polymorphism allele frequency, comparing cases and controls within each of the three populations tested</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Allele</td><td align="center" colspan="2">French-Canadian</td><td align="center" colspan="2">Tunisian</td><td align="center" colspan="2">Caucasian of European origin</td></tr></thead><tbody><tr><td></td><td align="center">Case (n = 100)</td><td align="center">Control (n = 102)</td><td align="center">Case (n = 67)</td><td align="center">Control (n = 46)</td><td align="center">Case (n = 122)</td><td align="center">Control (n = 125)</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">-1</td><td align="center">0.11</td><td align="center">0.15</td><td align="center">0.1</td><td align="center">0.11</td><td align="center">0.08</td><td align="center">0.1</td></tr><tr><td align="left">0</td><td align="center">0.87</td><td align="center">0.85</td><td align="center">0.86</td><td align="center">0.84</td><td align="center">0.91</td><td align="center">0.88</td></tr><tr><td align="left">+1</td><td align="center">0.03</td><td align="center">0.01</td><td align="center">0.04</td><td align="center">0.05</td><td align="center">0.01</td><td align="center">0.02</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 3.9, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.1</td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 0.2, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.5</td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 1.29, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.5</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Trinucleotide repeat polymorphism genotype frequency, comparing cases and controls within each of the three populations tested</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Genotype</td><td align="center" colspan="2">French-Canadian</td><td align="center" colspan="2">Tunisian</td><td align="center" colspan="2">Caucasian of European origin</td></tr></thead><tbody><tr><td></td><td align="center">Case (n = 100)</td><td align="center">Control (n = 102)</td><td align="center">Case (n = 67)</td><td align="center">Control (n = 46)</td><td align="center">Case (n = 122)</td><td align="center">Control (n = 125)</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">-1,0</td><td align="center">0.21</td><td align="center">0.25</td><td align="center">0.19</td><td align="center">0.2</td><td align="center">0.15</td><td align="center">0.18</td></tr><tr><td align="left">0,0</td><td align="center">0.74</td><td align="center">0.75</td><td align="center">0.73</td><td align="center">0.7</td><td align="center">0.83</td><td align="center">0.78</td></tr><tr><td align="left">0,+1</td><td align="center">0.05</td><td align="center">0.01</td><td align="center">0.07</td><td align="center">0.11</td><td align="center">0.02</td><td align="center">0.04</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 3.02, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.1</td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 0.41, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.5</td><td align="center" colspan="2"><italic>&#x003c7;</italic><sup>2 </sup>= 0.91, <italic>df </italic>= 2, <italic>p </italic>&#x0003e; 0.5</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Transmission Disequilibrium Test and FBAT analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Allele</td><td align="center">Allele Frequency</td><td align="center">No. of informative triads</td><td align="center">Z statistic</td><td align="center"><italic>p</italic></td></tr></thead><tbody><tr><td align="center">-1</td><td align="center">0.12</td><td align="center">53</td><td align="center">-2.12</td><td align="center">0.034</td></tr><tr><td align="center">0</td><td align="center">0.85</td><td align="center">67</td><td align="center">1.65</td><td align="center">0.099</td></tr><tr><td align="center">+1</td><td align="center">0.03</td><td align="center">23</td><td align="center">0.35</td><td align="center">0.72</td></tr></tbody></table></table-wrap><p>These results suggest that there is no association between the trinucleotide repeat polymorphism within <italic>SMARCA2 </italic>and schizophrenia. Although all subjects included in the study were carefully diagnosed according to DSM criteria, as having schizophrenia or schizoaffective disorder, one cannot exclude the phenotypic diversity that is inherent to the disorder. For example, within our French Canadian group of affected subjects, 70.7% were diagnosed with paranoid schizophrenia, 5.05% with the disorganized type, 2.02% with schizoaffective disorder and 22.22% with undifferentiated schizophrenia. There has been considerable discussion recently that in studying the genetics of schizophrenia and complex psychiatric disorders, in general, that it is necessary to examine suitable endophenotypes within the disorder rather than to examine the disorder as a whole [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. It remains important therefore to examine the association of this trinucleotide repeat polymorphism within <italic>SMARCA2 </italic>with specific endophenotypes resulting from neurodevelopmental deficits, given the importance of BRM in development and neural development in particular. Also given the minor effect detected with the family-based association study, it may be important to re-examine this polymorphism with a larger sample size.</p><p>This study also offers a step forward in understanding the polyglutamine domain within BRM. Although BRM has been shown to be important in transcriptional regulation, little is known about the role of the polyglutamine domain. In the populations we have studied, we have not observed an expansion of the trinucleotide repeat region, even though the number of glutamines (32) is close to the pathogenic threshold of ~35&#x02013;40 glutamines [<xref ref-type="bibr" rid="B20">20</xref>]. The trinucleotide repeat appears therefore to be stable, though polymorphic. We sequenced the trinucleotide repeat in six individuals, two each being homozygous for the -1, 0 and +1 alleles. The sequence encoded by this domain, in the 0 allele, is -<bold>Q</bold><sub>23</sub>-<bold>P</bold>- <bold>Q</bold><sub>3 </sub>-<bold>P</bold><sub>2 </sub>-<bold>Q</bold>- <bold>P</bold>-<bold>Q</bold>-. The sequence of the -1 allele was -<bold>Q</bold><sub>22 </sub>-P- Q<sub>3 </sub>-P<sub>2 </sub>-Q- P -Q- while the sequence of the +1 allele was -<bold>Q</bold><sub>24 </sub>-P- Q<sub>3 </sub>-P<sub>2 </sub>-Q- P -Q-. It therefore appears that the terminal CAG repeat in the first block of CAA/CAG repeats is the polymorphic site, at least in the individuals studied. This is consistent with results obtained in examining the different alleles at this locus in an Indian population [<xref ref-type="bibr" rid="B21">21</xref>]. Further functional studies would be important to assess the role of this polyglutamine domain in protein-DNA and protein-protein interactions. This may be informative particularly since this domain appears to be a conserved domain in BRM, which itself is a well conserved regulator of transcription.</p></sec><sec><title>Conclusion</title><p>Results from our family-based and case-control association study suggest that there is no association between the trinucleotide repeat polymorphism within <italic>SMARCA2 </italic>and schizophrenia.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Subjects diagnosed with schizophrenia or schizoaffective disorder, their families and unrelated healthy controls were recruited from three populations: Tunisian, French Canadian and other Caucasians of European origin. Patients were diagnosed using DSM-III-R or DSM-IV criteria on the basis of the Diagnostic Interview for Genetic Studies (DIGS) and complementary data from the medical files. Most of these subjects had previously participated in a pharmacogenetic study with a detailed evaluation of therapeutic response to medication [<xref ref-type="bibr" rid="B14">14</xref>]. For the family-based study, subjects and their families were recruited from mental health facilities in Montreal, Ottawa, Hungary, France, and Tunisia. A total of 281 complete (n = 182) and incomplete (n = 99) triads were genotyped (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Summary of subjects used in the family-based study</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">No of families</td><td align="center" colspan="3">No of triads</td></tr></thead><tbody><tr><td></td><td align="center">Families with one affected individual</td><td align="center">Families with more than one affected individual</td><td align="center">Total</td><td align="center">Complete triad</td><td align="center">Incomplete triad*</td><td align="center">Total</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">French Canadian</td><td align="center">41</td><td align="center">0</td><td align="center">41</td><td align="center">13</td><td align="center">28</td><td align="center">41</td></tr><tr><td align="left">Tunisian</td><td align="center">24</td><td align="center">12</td><td align="center">36</td><td align="center">52</td><td align="center">2</td><td align="center">54</td></tr><tr><td align="left">Other Caucasian of European origin-1</td><td align="center">58</td><td align="center">1</td><td align="center">59</td><td align="center">28</td><td align="center">35</td><td align="center">63</td></tr><tr><td align="left">Other Caucasian of European origin-2</td><td align="center">113</td><td align="center">5</td><td align="center">118</td><td align="center">89</td><td align="center">34</td><td align="center">123</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Total</td><td align="center">236</td><td align="center">19</td><td align="center">255</td><td align="center">182</td><td align="center">99</td><td align="center">281</td></tr></tbody></table><table-wrap-foot><p>* Incomplete triads include families with missing parent(s).</p><p>"Other Caucasian of European origin-1" included Caucasian triads (excluding French Canadian triads) recruited from Montreal and Ottawa.</p><p>"Other Caucasian of European origin-2" included Caucasian triads recruited from Hungary and France.</p></table-wrap-foot></table-wrap><p>Case/control analysis was conducted exclusively with subjects from Montreal, Ottawa and Tunisia since unaffected control subjects were not available for analysis from Hungary and France. This step was undertaken to minimize any effects arising due to population stratification. Unrelated cases (n = 289) and controls (n = 273) were used for the case-control analysis. The cases included (Table <xref ref-type="table" rid="T2">2</xref>): (<xref ref-type="table" rid="T1">1</xref>) unrelated probands (n = 123), recruited from Montreal, Ottawa, and Tunisia, who were included in the family-based analysis. Only probands from families having one affected individual were included for this case-control analysis (Table <xref ref-type="table" rid="T1">1</xref>), in order to avoid introducing bias by selecting between multiple affected individuals from a single family; (2) subjects (n = 166) recruited from mental health facilities in the three regions, for whom parent DNA samples were not available (termed "isolated cases"). Table <xref ref-type="table" rid="T2">2</xref> gives a detailed break-up of the ethnicities of the cases and controls.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Summary of subjects used in the case-control analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">Case</td><td align="center">Control</td></tr></thead><tbody><tr><td></td><td align="center">Cases included in family-based study*</td><td align="center">Isolated cases<sup>&#x02020;</sup></td><td align="center">Total</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">French Canadian</td><td align="center">41</td><td align="center">59</td><td align="center">100</td><td align="center">102</td></tr><tr><td align="left">Tunisian</td><td align="center">24</td><td align="center">43</td><td align="center">67</td><td align="center">46</td></tr><tr><td align="left">Other Caucasian of European origin-1</td><td align="center">58</td><td align="center">64</td><td align="center">122</td><td align="center">125</td></tr><tr><td align="left">Total</td><td align="center">123</td><td align="center">166</td><td align="center">289</td><td align="center">273</td></tr></tbody></table><table-wrap-foot><p>* Subjects from families having more than one affected individual were not included in the case/control study (please refer to Table 1). Only unrelated cases and controls were used for this analysis.</p><p><sup>&#x02020; </sup>Isolated cases were those subjects for whom parent DNA samples were not available.</p></table-wrap-foot></table-wrap><p>Controls were recruited in Montreal, Ottawa and Tunisia, either by newspaper advertisement or random sampling from a downtown population or open advertisement among the employees of the hospitals where the studies were conducted. Each control subject was evaluated by a trained clinician using the Structured Clinical Interview for DSM-IV, Non-patient edition (SCID-NP) to ensure that the individual did not have an ongoing or previous psychiatric illness. Written, informed consent was obtained from each patient and non-affected subject prior to beginning the study. The research protocol and the consent forms were approved by the Ethics Committee of each Institutional Review Board.</p></sec><sec><title>Genotyping</title><p>Genomic DNA was extracted from peripheral blood using standard procedures. The trinucleotide repeat within <italic>SMARCA2 </italic>was amplified by polymerase chain reaction (PCR) using the following primers: forward-5'TGCAGTCCAGGGGAAAAGGACGTT3', reverse-5'CCCGGGCCAGATGGTCTGTTGTAG3'. The forward primer was fluorescent labeled with 6-FAM&#x02122; (Applied Biosystems). A 15 &#x003bc;l PCR reaction, containing 10 ng DNA, 2.5 mM MgCl<sub>2</sub>, 0.25 mM of each dNTP, 0.33 &#x003bc;M of each primer, and 0.6 units Taq Polymerase was carried out. After initial denaturation at 94&#x000b0;C for 5 minutes, 35 cycles were carried out at 94&#x000b0;C for 1 min, 61.3&#x000b0;C for 1 min, 72&#x000b0;C for 1 min, followed by a final extension at 72&#x000b0;C for 30 min.</p><p>After verification of the PCR amplification by agarose gel electrophoresis, 0.5 &#x003bc;ls of each sample was mixed with 0.3 &#x003bc;ls size standard (GeneScan&#x02122; 500 LIZ&#x02122;) and 9.2 &#x003bc;ls deionized formamide (Applied Biosystems), denatured at 95&#x000b0;C for 5 minutes, and placed on ice. Each 96-well plate was analyzed using the ABI PRISM<sup>&#x000ae; </sup>3100 Genetic Analyzer and GeneScan v3.7. The sizes of the DNA fragments were obtained in comparison to the DNA standard using Genotyper<sup>&#x000ae; </sup>Software v3.7. The most frequently occurring allele, corresponding to a size of 181 bp (obtained using Genotyper<sup>&#x000ae;</sup>) was designated "0". The sizes of each of the respective alleles increased or decreased proportionately by 3 bps i.e. alleles -1, and +1 had sizes of 178 and 184 bps respectively.</p></sec><sec><title>Statistical analysis</title><p>The Transmission Disequilibrium Test [<xref ref-type="bibr" rid="B15">15</xref>] was conducted using the FBAT (Family-Based Association Tests) program [<xref ref-type="bibr" rid="B16">16</xref>]. Allele frequencies in affected subjects and non-affected controls were compared using the Pearson chi-square (<italic>&#x003c7;</italic><sup>2</sup>) statistic in Statistica<sup>&#x000ae;</sup>. Statistical significance was established at <italic>p </italic>&#x0003c; 0.05.</p></sec></sec><sec><title>Abbreviations</title><p>BRM &#x02013; Brahma</p><p>DIGS &#x02013; Diagnostic Interview for Genetic Studies</p><p>FBAT &#x02013; Family-Based Association Tests</p><p>PCR &#x02013; polymerase chain reaction</p><p>SCID-NP &#x02013; Structured Clinical Interview for DSM-IV, Non-patient edition</p><p>SCZ &#x02013; schizophrenia</p><p>SMARC &#x02013; SWI/SNF-related, matrix-associated, actin-dependant regulator of chromatin</p></sec><sec><title>Authors' contributions</title><p>SS, LX, FF performed the data analysis. SS drafted the manuscript. CB, KT, ZD, AL, SL, MK, GR and RJ were involved in the study design and provided clinical support. RJ was responsible for the conception of the study, supervision of the research project and drafting of the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>SS and LX were supported by a fellowship from the Genes, Environment and Health Training Program at McGill University, funded by Institute of Neurosciences, Mental Health and Addiction/Fonds de la recherche en sant&#x000e9; du Quebec. This work was supported by a grant from the Sackler Foundation.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sif</surname><given-names>S</given-names></name></person-group><article-title>ATP-dependent nucleosome remodeling complexes: enzymes tailored to deal with chromatin</article-title><source>J Cell Biochem</source><year>2004</year><volume>91</volume><fpage>1087</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">15048866</pub-id><pub-id pub-id-type="doi">10.1002/jcb.20005</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Cairns</surname><given-names>BR</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name></person-group><article-title>Diversity and specialization of mammalian SWI/SNF complexes</article-title><source>Genes Dev</source><year>1996</year><volume>10</volume><fpage>2117</fpage><lpage>2130</lpage><pub-id pub-id-type="pmid">8804307</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>TW</given-names></name><name><surname>Link</surname><given-names>KA</given-names></name><name><surname>Petre-Draviam</surname><given-names>CE</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><article-title>Differential requirement of SWI/SNF for androgen receptor activity</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>30605</fpage><lpage>30613</lpage><pub-id pub-id-type="pmid">12775722</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M304582200</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadam</surname><given-names>S</given-names></name><name><surname>Emerson</surname><given-names>BM</given-names></name></person-group><article-title>Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes</article-title><source>Mol Cell</source><year>2003</year><volume>11</volume><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">12620226</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00034-0</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>JC</given-names></name><name><surname>Barra</surname><given-names>J</given-names></name><name><surname>Muchardt</surname><given-names>C</given-names></name><name><surname>Camus</surname><given-names>A</given-names></name><name><surname>Babinet</surname><given-names>C</given-names></name><name><surname>Yaniv</surname><given-names>M</given-names></name></person-group><article-title>Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha)</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><fpage>6979</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">9843504</pub-id><pub-id pub-id-type="doi">10.1093/emboj/17.23.6979</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakak</surname><given-names>Y</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Fienberg</surname><given-names>AA</given-names></name></person-group><article-title>Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>4746</fpage><lpage>4751</lpage><pub-id pub-id-type="pmid">11296301</pub-id><pub-id pub-id-type="doi">10.1073/pnas.081071198</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hemby</surname><given-names>SE</given-names></name><name><surname>Ginsberg</surname><given-names>SD</given-names></name><name><surname>Brunk</surname><given-names>B</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Eberwine</surname><given-names>JH</given-names></name></person-group><article-title>Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex</article-title><source>Arch Gen Psych</source><year>2002</year><volume>59</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.59.7.631</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holstege</surname><given-names>FC</given-names></name><name><surname>Jennings</surname><given-names>EG</given-names></name><name><surname>Wyrick</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Hengartner</surname><given-names>CJ</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><article-title>Dissecting the regulatory circuitry of a eukaryotic genome</article-title><source>Cell</source><year>1998</year><volume>95</volume><fpage>717</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">9845373</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81641-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sudarsanam</surname><given-names>P</given-names></name><name><surname>Iyer</surname><given-names>VR</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Winston</surname><given-names>F</given-names></name></person-group><article-title>Whole-genome expression analysis of snf/swi mutants of Saccharomyces cerevisiae</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>3364</fpage><lpage>3369</lpage><pub-id pub-id-type="pmid">10725359</pub-id><pub-id pub-id-type="doi">10.1073/pnas.050407197</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>JJ</given-names></name><name><surname>Feron</surname><given-names>FP</given-names></name><name><surname>Burne</surname><given-names>TH</given-names></name><name><surname>Mackay-Sim</surname><given-names>A</given-names></name><name><surname>Eyles</surname><given-names>DW</given-names></name></person-group><article-title>The neurodevelopmental hypothesis of schizophrenia: a review of recent developments</article-title><source>Ann Med</source><year>2003</year><volume>35</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12795338</pub-id><pub-id pub-id-type="doi">10.1080/07853890310010005</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machida</surname><given-names>Y</given-names></name><name><surname>Murai</surname><given-names>K</given-names></name><name><surname>Miyake</surname><given-names>K</given-names></name><name><surname>Iijima</surname><given-names>S</given-names></name></person-group><article-title>Expression of chromatin remodeling factors during neural differentiation</article-title><source>J Biochem (Tokyo)</source><year>2001</year><volume>129</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">11134956</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Raff</surname><given-names>M</given-names></name></person-group><article-title>Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>2963</fpage><lpage>2972</lpage><pub-id pub-id-type="pmid">15574597</pub-id><pub-id pub-id-type="doi">10.1101/gad.309404</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segurado</surname><given-names>R</given-names></name><name><surname>Detera-Wadleigh</surname><given-names>SD</given-names></name><name><surname>Levinson</surname><given-names>DF</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><name><surname>Craddock</surname><given-names>N</given-names></name><name><surname>DePaulo</surname><given-names>JR</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Gershon</surname><given-names>ES</given-names></name><name><surname>Ekholm</surname><given-names>J</given-names></name><name><surname>Cichon</surname><given-names>S</given-names></name><name><surname>Turecki</surname><given-names>G</given-names></name><name><surname>Claes</surname><given-names>S</given-names></name><name><surname>Kelsoe</surname><given-names>JR</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Badenhop</surname><given-names>RF</given-names></name><name><surname>Morissette</surname><given-names>J</given-names></name><name><surname>Coon</surname><given-names>H</given-names></name><name><surname>Blackwood</surname><given-names>D</given-names></name><name><surname>McInnes</surname><given-names>LA</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Reich</surname><given-names>T</given-names></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>McInnis</surname><given-names>MG</given-names></name><name><surname>McMahon</surname><given-names>FJ</given-names></name><name><surname>Badner</surname><given-names>JA</given-names></name><name><surname>Goldin</surname><given-names>LR</given-names></name><name><surname>Bennett</surname><given-names>P</given-names></name><name><surname>Willour</surname><given-names>VL</given-names></name><name><surname>Zandi</surname><given-names>PP</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gilliam</surname><given-names>C</given-names></name><name><surname>Juo</surname><given-names>SH</given-names></name><name><surname>Berrettini</surname><given-names>WH</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Lonnqvist</surname><given-names>J</given-names></name><name><surname>Nothen</surname><given-names>MM</given-names></name><name><surname>Schumacher</surname><given-names>J</given-names></name><name><surname>Windemuth</surname><given-names>C</given-names></name><name><surname>Rietschel</surname><given-names>M</given-names></name><name><surname>Propping</surname><given-names>P</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Alda</surname><given-names>M</given-names></name><name><surname>Grof</surname><given-names>P</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Del-Favero</surname><given-names>J</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Mendlewicz</surname><given-names>J</given-names></name><name><surname>Adolfsson</surname><given-names>R</given-names></name><name><surname>Spence</surname><given-names>MA</given-names></name><name><surname>Luebbert</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>LJ</given-names></name><name><surname>Donald</surname><given-names>JA</given-names></name><name><surname>Mitchell</surname><given-names>PB</given-names></name><name><surname>Barden</surname><given-names>N</given-names></name><name><surname>Shink</surname><given-names>E</given-names></name><name><surname>Byerley</surname><given-names>W</given-names></name><name><surname>Muir</surname><given-names>W</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name><name><surname>Macgregor</surname><given-names>S</given-names></name><name><surname>Gurling</surname><given-names>H</given-names></name><name><surname>Kalsi</surname><given-names>G</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Escamilla</surname><given-names>MA</given-names></name><name><surname>Reus</surname><given-names>VI</given-names></name><name><surname>Leon</surname><given-names>P</given-names></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Ewald</surname><given-names>H</given-names></name><name><surname>Kruse</surname><given-names>TA</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><name><surname>Radhakrishna</surname><given-names>U</given-names></name><name><surname>Blouin</surname><given-names>JL</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Akarsu</surname><given-names>N</given-names></name></person-group><article-title>Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder</article-title><source>Am J Hum Genet</source><year>2003</year><volume>73</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12802785</pub-id><pub-id pub-id-type="doi">10.1086/376547</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joober</surname><given-names>R</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Lal</surname><given-names>S</given-names></name><name><surname>Dixon</surname><given-names>M</given-names></name><name><surname>O'Driscoll</surname><given-names>G</given-names></name><name><surname>Palmour</surname><given-names>R</given-names></name><name><surname>Annable</surname><given-names>L</given-names></name><name><surname>Bloom</surname><given-names>D</given-names></name><name><surname>Lalonde</surname><given-names>P</given-names></name><name><surname>Labelle</surname><given-names>A</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name></person-group><article-title>Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers</article-title><source>Schizophr Res</source><year>2002</year><volume>53</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">11738536</pub-id><pub-id pub-id-type="doi">10.1016/S0920-9964(01)00279-1</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spielman</surname><given-names>RS</given-names></name><name><surname>McGinnis</surname><given-names>RE</given-names></name><name><surname>Ewens</surname><given-names>WJ</given-names></name></person-group><article-title>Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)</article-title><source>Am J Hum Genet</source><year>1993</year><volume>52</volume><fpage>506</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">8447318</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laird</surname><given-names>NM</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Implementing a unified approach to family-based tests of association</article-title><source>Genet Epidemiol</source><year>2000</year><volume>19</volume><fpage>S36</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11055368</pub-id><pub-id pub-id-type="doi">10.1002/1098-2272(2000)19:1+&#x0003c;::AID-GEPI6&#x0003e;3.0.CO;2-M</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hallmayer</surname><given-names>JF</given-names></name><name><surname>Kalaydjieva</surname><given-names>L</given-names></name><name><surname>Badcock</surname><given-names>J</given-names></name><name><surname>Dragovic</surname><given-names>M</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Michie</surname><given-names>PT</given-names></name><name><surname>Rock</surname><given-names>D</given-names></name><name><surname>Vile</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Corder</surname><given-names>EH</given-names></name><name><surname>Hollingsworth</surname><given-names>K</given-names></name><name><surname>Jablensky</surname><given-names>A</given-names></name></person-group><article-title>Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>468</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">16080121</pub-id><pub-id pub-id-type="doi">10.1086/432816</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiser</surname><given-names>M</given-names></name><name><surname>van Os</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>M</given-names></name></person-group><article-title>Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes</article-title><source>Br J Psych</source><year>2005</year><volume>187</volume><fpage>203</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1192/bjp.187.3.203</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottesman</surname><given-names>II</given-names></name><name><surname>Gould</surname><given-names>TD</given-names></name></person-group><article-title>The endophenotype concept in psychiatry: etymology and strategic intentions</article-title><source>Am J Psych</source><year>2003</year><volume>160</volume><fpage>636</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.160.4.636</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>CJ</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><article-title>Trinucleotide repeats: Mechanisms and pathology</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>1</volume><fpage>281</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">11701632</pub-id><pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.281</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>N</given-names></name><name><surname>Mittal</surname><given-names>U</given-names></name><name><surname>Srivastava</surname><given-names>AK</given-names></name><name><surname>Mukerji</surname><given-names>M</given-names></name></person-group><article-title>SMARCA2 and THAP11: potential candidates for polyglutamine disorders as evidenced from polymorphism and protein-folding simulation studies</article-title><source>J Hum Genet</source><year>2004</year><volume>49</volume><fpage>596</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">15368101</pub-id><pub-id pub-id-type="doi">10.1007/s10038-004-0194-8</pub-id></citation></ref></ref-list></back></article> 